Building a platform for long-term growth and impact
2024 annual report
Our purpose is to invest to extend and enhance human life
Watch video
Our team members are experts at what they do
Our people
A diversified portfolio of life science companies
Portfolio

To unlock the potential from truly innovative science to transform patients’ lives

We create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading healthcare businesses

Who we are

A diversified portfolio across clinical stages

Late-stage clinical companies
Late-stage clinical companies
Clinical companies
Clinical companies
Pre-clinical companies
Pre-clinical companies
Explore our portfolio

Making a positive contribution

We are committed to managing our business in a sustainable way, investing responsibly, and supporting our portfolio companies in making positive contributions to society by developing treatments that will make a difference to the lives of patients and their families.

Sustainability

Latest news

Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson’s Disease at 2025 GBA1 Meeting

iOnctura bolsters leadership team with new appointments

Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for FLT201, its Clinical-Stage Gene Therapy Candidate in Gaucher Disease

Slingshot Therapeutics strengthens its team through the appointment of Ed Savory as Head of Chemistry

Resolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025

Kesmalea Therapeutics Appoints Industry Veteran Tim Clackson to Board of Directors

iOnctura commences randomised Phase I/II study in non-small cell lung cancer

Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025

Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation

Autolus Therapeutics Announces License of AUCATZYL®

iOnctura commences randomized Phase II study in metastatic uveal melanoma

Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer

OMass Therapeutics appoints Birgitte Volck as Non-Executive Director

Third Quarter Results FY2025

Spur Therapeutics Announces Positive Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Gene Therapy Candidate for Gaucher Disease, at WORLDSymposium™

Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease

Yellowstone Biosciences appoints Dr. Ita O’Kelly, previously Executive Director Product Management at Immunocore, as its Chief Operating Officer and a member of its Leadership Team

Beacon Therapeutics Granted FDA Regenerative Medicine Advanced Therapy (RMAT)

View all news
2024 Annual Report front cover

2024 Annual Report

Our Annual Report and Accounts 2024 provides an overview of our most recent financial year, as we continue to execute our clear strategy for growth and patient impact.

03.07.24 | pdf (4.55Mb)
Download

An expert multi-disciplinary team, attracting world-class talent

We are differentiated by our people, who identify innovative technology and take a commercial approach to building businesses capable of delivering transformational treatments to patients.

Our people

Search